Eva L Kneepkens1, Mieke F Pouw1,2, Gerrit Jan Wolbink1,2, Tiny Schaap3, Michael T Nurmohamed1,4, Annick de Vries3, Theo Rispens2, Karien Bloem2,3. 1. Rheumatology, Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, The Netherlands. 2. Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Centre Amsterdam, Amsterdam, The Netherlands. 3. Biologicals Lab, Sanquin Diagnostic Services, Amsterdam, The Netherlands. 4. Rheumatology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, The Netherlands.
Abstract
AIMS: Development of a self-sampling method for therapeutic drug monitoring (TDM) of biologicals will enhance TDM implementation in routine care and pharmacokinetic knowledge. The aim of this study was to compare adalimumab and anti-adalimumab antibody (ADA) concentration measurements in dried blood spots (DBS) obtained from finger prick with measurements in serum obtained via venepuncture, from patients with rheumatic inflammatory diseases. METHODS: In this cross-sectional study, 161 consecutive patients were included. For clinical validation, DBS from finger prick and serum from venepuncture were collected simultaneously and adalimumab and ADA concentration were assessed by ELISA and antigen binding test (ABT), respectively. To convert DBS eluate results to values which can be compared to serum concentrations, five different methods were investigated, using a marker protein or a volumetric approach. RESULTS: Adalimumab and ADA concentrations obtained from the finger prick/DBS method correlated well with serum results from the same patient (correlation coefficient > 0.87). Interestingly, antibody concentrations (either adalimumab, ADA or total immunoglobulin G) in DBS from finger prick, but not albumin, were systematically lower compared to serum. Spike experiments demonstrated a quantitative recovery for all tested proteins in DBS, suggesting a slightly different protein composition of blood collected via finger prick vs. venepuncture. We established a correction factor to relate finger prick/DBS values with serum values (approximately 1.2). CONCLUSIONS: We show here for the first time that adalimumab and ADA serum concentrations can be satisfactorily estimated by measuring concentrations in DBS eluates, collected by finger prick. This method offers great opportunity to simplify TDM of adalimumab.
AIMS: Development of a self-sampling method for therapeutic drug monitoring (TDM) of biologicals will enhance TDM implementation in routine care and pharmacokinetic knowledge. The aim of this study was to compare adalimumab and anti-adalimumab antibody (ADA) concentration measurements in dried blood spots (DBS) obtained from finger prick with measurements in serum obtained via venepuncture, from patients with rheumatic inflammatory diseases. METHODS: In this cross-sectional study, 161 consecutive patients were included. For clinical validation, DBS from finger prick and serum from venepuncture were collected simultaneously and adalimumab and ADA concentration were assessed by ELISA and antigen binding test (ABT), respectively. To convert DBS eluate results to values which can be compared to serum concentrations, five different methods were investigated, using a marker protein or a volumetric approach. RESULTS:Adalimumab and ADA concentrations obtained from the finger prick/DBS method correlated well with serum results from the same patient (correlation coefficient > 0.87). Interestingly, antibody concentrations (either adalimumab, ADA or total immunoglobulin G) in DBS from finger prick, but not albumin, were systematically lower compared to serum. Spike experiments demonstrated a quantitative recovery for all tested proteins in DBS, suggesting a slightly different protein composition of blood collected via finger prick vs. venepuncture. We established a correction factor to relate finger prick/DBS values with serum values (approximately 1.2). CONCLUSIONS: We show here for the first time that adalimumab and ADA serum concentrations can be satisfactorily estimated by measuring concentrations in DBS eluates, collected by finger prick. This method offers great opportunity to simplify TDM of adalimumab.
Authors: Philip Timmerman; Steve White; Zoe Cobb; Ronald de Vries; Elizabeth Thomas; Ben van Baar Journal: Bioanalysis Date: 2013-07-05 Impact factor: 2.681
Authors: Erik H Vogelzang; Eva L Kneepkens; Michael T Nurmohamed; Arno W R van Kuijk; Theo Rispens; Gertjan Wolbink; Charlotte L M Krieckaert Journal: Ann Rheum Dis Date: 2014-08-12 Impact factor: 19.103
Authors: Mieke F Pouw; Charlotte L Krieckaert; Michael T Nurmohamed; Desiree van der Kleij; Lucien Aarden; Theo Rispens; Gertjan Wolbink Journal: Ann Rheum Dis Date: 2013-12-10 Impact factor: 19.103
Authors: Eva L Kneepkens; James Cheng-Chung Wei; Michael T Nurmohamed; Kai-Jieh Yeo; C Y Chen; Irene E van der Horst-Bruinsma; Desiree van der Kleij; Theo Rispens; Gertjan Wolbink; Charlotte L M Krieckaert Journal: Ann Rheum Dis Date: 2013-12-10 Impact factor: 19.103
Authors: Iris Detrez; Ganel Schops; Jolien Lefrère; Sophie Tops; Gert Van Assche; Séverine Vermeire; Wouter Van Moerkercke; Marc Ferrante; Ann Gils Journal: AAPS J Date: 2018-12-18 Impact factor: 4.009
Authors: Eva L Kneepkens; Mieke F Pouw; Gerrit Jan Wolbink; Tiny Schaap; Michael T Nurmohamed; Annick de Vries; Theo Rispens; Karien Bloem Journal: Br J Clin Pharmacol Date: 2017-08-22 Impact factor: 4.335
Authors: Sophie E Berends; Geert R A M D'Haens; Tiny Schaap; Annick de Vries; Theo Rispens; Karien Bloem; Ron A A Mathôt Journal: Br J Clin Pharmacol Date: 2019-05-11 Impact factor: 4.335
Authors: N Van den Berghe; E De Keyser; R Soenen; L Meuleman; S Lanssens; A Gils; J Lambert Journal: Br J Dermatol Date: 2019-07-24 Impact factor: 9.302
Authors: S W Tas; G J Wolbink; L Boekel; F Hooijberg; E H Vogelzang; P L Klarenbeek; W H Bos Journal: Arthritis Res Ther Date: 2021-08-05 Impact factor: 5.156